Chinese Scientists Pioneer 20X Enhanced Quercetin for COPD Relief: Clinical Trial Shows 52.6% Oxidative Damage Reduction

A landmark phytosome technology breakthrough led by Professor Wu Ruling has elevated quercetin absorption from 4.9% to 98%, enabling unprecedented efficacy against chronic obstructive pulmonary disease (COPD)—now China’s third-leading cause of death.

The COPD Crisis & Scientific Breakthrough

1. Epidemiological Urgency:

   • COPD affects 120 million Chinese, with 10–20 million new cases annually (China Health Management Association).
   • Respiration expert Chao Enxiang warns: "Early intervention within 3 months of symptom onset can halt disease progression."

2. Phytosome® Technology (US5043323):

   • Overcomes quercetin’s historically low bioavailability (4.9%) using patented lipid encapsulation.
   • FDA-recognized clinical efficacy: 20X enhanced quercetin achieves 98% absorption without liver/kidney burden.

Clinical Validation: Rebuilding Lung Barriers in 6 Weeks

⓵ Primary Trial (500 COPD Patients):

⓶ "JiQingFei" Formula Synergy:

• Combines 20X quercetin with Citrus reticulata extract and co-crystal olive leaf extract (Patent ZL202110243777.0).
• Stanford Clinical Study (n=350):
  • Lung tissue repair: ↑37.1% histological improvement
  • Abnormal cell reduction: 99.3% efficacy
  • 99.7% user-reported ease of breathing (JD.com consumer data).

Commercial Impact & Global Recognition

1. Licensing Partnership:
   • Nature’s Dream secured global rights for $5.7M, leveraging 40+ patents.
2. Market Validation:
   • JD.com sales: 2,000 bottles/day; 632% search surge in launch month.
   • Awarded "Breakthrough Brand" on Tmall/JD’s GRANVER flagship.
3. Global Endorsement:
   • Wall Street Journal cites JiQingFei as "pulmonary health’s commercial magnet."

Mechanism: Triple-Action Lung Defense

1. Oxidative Shield: Neutralizes free radicals in alveoli.
2. Tissue Regeneration: Stimulates parenchymal cell repair.
3. Anti-Inflammatory Pathway: Modulates cytokine release.